Broadens Lilly’s immunology pipeline with Morphic’s oral integrin therapies, including MORF-057 Reinforces the company’s strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ — Eli Lilly and Company…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.